CRISM reports 'significant' preclinical data for prostate cancer drug
CRISM Therapeutics Corp said on Tuesday that preclinical studies show that its ChemoSeed drug delivery platform could ‘could substantially enhance’ the efficacy of docetaxel in the treatment of prostate cancer.
The British Virgin Islands-based pharmaceutical firm reported ‘significant preclinical findings’ showing that sustained administration of docetaxel killed 72% of cancer cells compared to 65% with intermittent dosing, which is used in the current standard of care.
CRISM said it has formulated docetaxel within the ChemoSeed platform, achieving sustained drug release over a period of at least 28 days.
The company said it has been awarded a Department for the Economy collaborative doctoral partnership studentship in collaboration with Ulster University.
This partnership will support the ongoing development of docetaxel-ChemoSeed and explore its application in the personalised treatment of prostate cancer.
Chief Executive Officer of CRISM Andrew Webb said: ‘These developments represent a major step forward in our mission to improve outcomes for prostate cancer patients by leveraging our ChemoSeed drug delivery platform.
‘The data clearly suggest that delivering chemotherapy locally and continuously, rather than intermittently and systemically, could provide a much-needed improvement in therapeutic efficacy.’
Shares in CRISM fell 7.0% to 10.23 pence in London on Tuesday afternoon.
Copyright 2025 Alliance News Ltd. All Rights Reserved.